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Introduction: Breast cancer, the most common cause of cancer-related deaths worldwide among women, is a
molecularly and clinically heterogeneous disease. Extensive genetic and epigenetic profiling of breast tumors has
recently revealed novel putative driver genes, including p21-activated kinase (PAK)1. PAK1 is a serine/threonine
kinase downstream of small GTP-binding proteins, Rac1 and Cdc42, and is an integral component of growth factor
signaling networks and cellular functions fundamental to tumorigenesis.
Methods: PAK1 dysregulation (copy number gain, mRNA and protein expression) was evaluated in two cohorts of
breast cancer tissues (n = 980 and 1,108). A novel small molecule inhibitor, FRAX1036, and RNA interference were
used to examine PAK1 loss of function and combination with docetaxel in vitro. Mechanism of action for the
therapeutic combination, both cellular and molecular, was assessed via time-lapse microscopy and immunoblotting.
Results: We demonstrate that focal genomic amplification and overexpression of PAK1 are associated with poor
clinical outcome in the luminal subtype of breast cancer (P = 1.29 × 10−4 and P = 0.015, respectively). Given the role
for PAK1 in regulating cytoskeletal organization, we hypothesized that combination of PAK1 inhibition with taxane
treatment could be combined to further interfere with microtubule dynamics and cell survival. Consistent with this,
administration of docetaxel with either a novel small molecule inhibitor of group I PAKs, FRAX1036, or PAK1 small
interfering RNA oligonucleotides dramatically altered signaling to cytoskeletal-associated proteins, such as stathmin,
and induced microtubule disorganization and cellular apoptosis. Live-cell imaging revealed that the duration of
mitotic arrest mediated by docetaxel was significantly reduced in the presence of FRAX1036, and this was associated
with increased kinetics of apoptosis.
Conclusions: Taken together, these findings further support PAK1 as a potential target in breast cancer and suggest
combination with taxanes as a viable strategy to increase anti-tumor efficacy.* Correspondence: rudolph.joachim@gene.com; klaushoeflich@hotmail.com
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The p21-activated kinases (PAKs) have generated signifi-
cant interest as therapeutic targets in cancer [1,2]. The
PAK family is comprised of six members and is subdi-
vided into two groups (Groups I and II) based on se-
quence and structural homology. PAKs are currently
amongst the most well-characterized effector proteins of
the Ras-related C3 botulinum toxin substrate 1 (Rac)
and cell division control protein 42 (Cdc42). These
GTPases stimulate PAK catalytic activity by relieving an
intramolecular interaction between the kinase and auto-
inhibitory domains. The kinase domains of Group I ver-
sus II PAKs share approximately 50% identity and also
share homology with additional members of the sterile-
20 (STE20) subfamily of the kinome that are upstream
activators of mammalian mitogen-activated protein kin-
ase (MAPK) pathways.
PAK1 signaling has been shown to be important for
regulating cytoskeletal organization and cell migration
via both its catalytic activity and protein-protein interac-
tions. For instance, PAK1 modulates the activity of myosin
II (an actin interacting motor protein that can drive cell
contractility), LIM-kinase (involved in actin polymerization
through inactivation of cofilin family proteins) and filamin
A (a large actin-binding protein that induces membrane
ruffling) [3]. PAK1 is also involved in the phosphorylation
of proteins that control microtubule dynamics such as
stathmin, which destabilizes microtubules by binding tubu-
lin dimers to inhibit tubulin polymerization and promote
microtubule disassembly [4]. In addition, PAK1 phosphory-
lates tubulin cofactor B to augment heterodimerization of
tubulin [5] as well as dynein light chain 1 which is a com-
ponent of the cytoplasmic dynein complex that moves
along with microtubules [6]. To date, the evidence for the
role of PAK1 in microtubule remodeling comes primarily
from overexpression and genetic studies. For instance,
PAK1−/− mouse embryonic fibroblasts display decreased
microtubule regrowth and polymerization compared with
wild-type cells, and the reciprocal phenotypic was observed
using MCF7 breast cancer cells overexpressing PAK1 [7].
The contribution of PAK1 catalytic activity to microtubule
dynamics has yet to be thoroughly explored.
In addition to its role in regulation of the cytoskeleton,
PAK1 has been implicated in cellular processes that dir-
ectly contribute to tumorigenesis, including growth factor
pathways, cell proliferation, and pro-survival signaling [8].
PAK1 is also an effector of well-established oncogenes,
such as the Ras small monomeric GTPase which is mu-
tated in approximately 30% of human tumors. Given that
Rac and Cdc42 lie downstream of Ras [9,10], several
groups have evaluated the contribution of PAKs to Ras-
driven cellular transformation and in vivo tumorigenesis
[11,12]. For instance, PAK1 deletion in a mouse model of
Ras-driven cutaneous squamous cell carcinoma led tomarkedly decreased tumorigenesis and progression, which
was accompanied by attenuated signaling through MAPK
and cytoskeletal pathways [11].
In terms of direct dysregulation in cancer, PAK1 is
amplified, overexpressed or hyperactivated in several
tumor subtypes [1,13]. Of note, focal genomic amplifica-
tion of PAK1 at 11q14.1 has been reported for hormone
receptor-positive breast carcinoma [14,15]. Analysis of
breast cancer cell lines with PAK1 genomic copy num-
ber gain using RNA interference approaches revealed
dependence on PAK1 expression for cell survival [14]
and transformation [16]. Consistent with these findings,
functional studies using transgenic mouse models have
also demonstrated that overexpression of PAK1 in the
mammary gland promotes the formation of preneoplas-
tic lesions and breast tumors [17] and that PAK1 con-
tributes to human endothelial growth factor receptor 2
(HER2)/Neu-driven tumorigenesis [18].
However, given this emerging body of work, a detailed
assessment of PAK1 copy number alteration and valid-
ation experiments using small molecule inhibitors to
evaluate PAK1 catalytic inhibition in breast cancer are
still lacking. Moreover, the potential efficacy of PAK1 in-
hibition in combination with additional inhibitors of
cytoskeletal organization has yet to be examined. Herein,
we demonstrate that PAK1 gene amplification and pro-
tein overexpression are associated with poor clinical out-
come in a large collection of luminal breast cancers. We
also introduce a novel ATP-competitive small molecule
inhibitor of group I PAKs, FRAX1036, and demonstrate
sensitivity of PAK1-amplified breast cancer cells to this
compound. Taken together, these results suggest that
further investigation of PAK1 as a therapeutic target in
breast cancer is warranted. Given that PAK1 regulates
the cytoskeleton and microtubule inhibitors are used as
standard-of-care chemotherapy in advanced breast can-
cer, we explored the molecular and cellular mechanisms
for this therapeutic combination and showed increased
anti-tumor efficacy in breast cancer cells.
Materials and methods
Materials, cell culture and viability assays
FRAX1036 was synthesized by Afraxis, Inc. (La Jolla, CA,
USA) and docetaxel was purchased from Selleck Chemicals
(Houston, TX, USA). Antibodies used for immunoblotting
(p-MEK1-S298, p-CRAF-S338, Cleaved PARP, Cyclin D1,
p-Stathmin-S16, p-β-catenin-S675, MCL-1, BCL-xL, p-Bad-
S112 and PAK1) were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA); anti-Actin was purchased
from Sigma (St Louis, MO, USA). Cell lines were acquired
from the American Type Culture Collection (ATCC;
Manassas, VA, USA) and maintained at 37°C and 5% CO2
in RPMI 1640 media with 10% fetal bovine serum and
2 mM L-glutamine. U2OS-red fluorescent protein (RFP)-
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stably transduced with a plasmid expressing green fluores-
cent protein (GFP)-histone H2B. Cell transfections and
treatments were performed using short interfering RNA ol-
igonucleotides for PAK1 from Dharmacon RNAi Technolo-
gies (Chicago, IL, USA). Cellular viability was assessed via
ATP content using the CellTiter-Glo Luminescent Assay
(Promega, Madison, WI, USA) and results represent
mean ± standard deviation from three experiments.
PAK1/CCND1 survival analysis
Breast tumors from the Molecular Taxonomy of Breast
Cancer International Consortium (METABRIC) dataset
[15] with survival and DNA copy number data were se-
lected, yielding 980 patients. DNA copy number was cal-
culated using Affymetrix SNP6.0 arrays and a modified
version of the PICNIC algorithm [19], published recently
[20]. Samples were identified as having amplification of
either PAK1 or CCND1 if the absolute copy number of
the respective gene was >5 copies. The Kaplan-Meier
plot and log-rank test were performed using the cen-
sored survival values (days since diagnosis) provided
with the METABRIC dataset and our calculated PAK1
amplification status using the R language [21], version
3.1, and the R package “survival”, version 2.37-7.
A Cox proportional hazard model was constructed using
the METABRIC censored survival data, Nottingham prog-
nostic index (NPI), patient age, and patient PAM50 breast
cancer subtype classification in addition to the interaction
of CCND1 and PAK1 amplification statuses. More specif-
ically, the model “survival ~ NPI + age + PAM50 +CCND1
* PAK1” was fit using the “coxph” R package, where ccnd1
and pak1 are binary variables, as discussed above. The for-
est plot was produced using the coefficients from this
model and their P-values. The whiskers on this plot repre-
sent ±1.96 × the standard error for each coefficient. The
coefficient for amplification of both CCND1 and PAK1
(dual amplification) in the same sample was calculated as
the sum of the coefficients “pak1Amplified”, “ccnd1Ampli-
fied”, and the coefficient for the interaction term for these
two terms.
Bliss analysis
Cellular viability was assessed via ATP content using the
CellTiter-Glo Luminescent Assay (Promega, Fitchburg, WI,
USA) after a 4-day incubation period, and results represent
mean ± standard deviation from three experiments. Total
luminescence was measured on a Wallac Multilabel Reader
(Perkin-Elmer, Waltham, MA, USA). Cells were treated
simultaneously with FRAX1036 (dose range = 0 to 5 μM) or
docetaxel (dose range = 0 to 0.4 nM) in an 8 × 10 matrix of
concentrations. Combination synergy of FRAX1036 and do-
cetaxel was determined by Bliss independence analyses. A
Bliss expectation for a combined response C was calculatedby the equation: C = (A + B) - (A × B) where A and B are
the fractional growth inhibitions of given doses of drug A
and B. ΔBliss scores were summed across the dose matrix
to generate a Bliss sum. Bliss sum = 0 indicates that the
combination effect is additive while Bliss sum >0 indicates
synergy effect and Bliss sum <0 indicates antagonism ef-
fect. Statistical analysis comparing the Bliss sums for each
cell line was conducted by the Student’s t test.
Biochemical assays
The activity/inhibition of human recombinant PAK1
(kinase domain), PAK2 (full length) or PAK4 (kinase do-
main) was estimated by measuring the phosphorylation of a
FRET peptide substrate (Ser/Thr19) labeled with Coumarin
and Fluorescein using Z’-LYTE™ assay (Invitrogen, Carlsbad,
CA, USA). The 10 μL assay mixtures contained 50 mM
HEPES (pH 7.5), 0.01% Brij-35, 10 mM MgCl2, 1 mM
EGTA, 2 μM FRET peptide substrate, and PAK enzyme (20
pM PAK1; 50 pM PAK2; 90 pM PAK4). Incubations were
carried out at 22°C in black polypropylene 384-well plates
(Corning Costar, Corning, NY, USA). Prior to the assay, en-
zyme, FRET peptide substrate and serially diluted test com-
pounds were preincubated together in assay buffer (7.5 μL)
for 10 minutes, and the assay was initiated by the addition
of 2.5 μL assay buffer containing 4× ATP (160 μM PAK1;
480 μM PAK2; 16 μM PAK4). Following the 60-minute in-
cubation, the assay mixtures were quenched by the addition
of 5 μL of Z’-LYTE™ development reagent, and 1 hour later
the emissions of Coumarin (445 nm) and Fluorescein
(520 nm) were determined after excitation at 400 nm using
an Envision plate reader (Perkin Elmer). An emission ratio
(445 nm/520 nm) was determined to quantify the degree of
substrate phosphorylation.
Immunoblotting
Protein extracts were prepared at 4°C with RIPA Lysis
Buffer (EMD Millipore Corporation, Billerica, MA,
USA), 1 mM phenylmethylsulphonyl fluoride, Phosphat-
ase Inhibitor Cocktail 2/3 and protease inhibitor cocktail
(Sigma-Aldrich). For Western blot analysis, proteins
were resolved by 4 to 12% SDS-PAGE and transferred
to nitrocellulose membranes (Life Technologies, Grand
Island, NY, USA). Immunoblotting was performed using
the indicated primary antibodies and analyzed using
secondary antibodies for enhanced chemiluminescence.
IncuCyte apoptosis assays
For caspase 3/7 activation apoptosis assays, cells were
plated at 10,000 cells/well in 96-well Corning plates for
24 hours prior to treating with DMSO, FRAX1036, and/or
docetaxel. Caspase 3/7 reagent was added at a 1:1000 dilu-
tion (Essen Bioscience No. 4440, Ann Arbor, MI, USA).
Cells were imaged at 10× magnification in an IncuCyte
Zoom Live-content imaging system (Essen Bioscience) at
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4 hours for 36 to 72 hours, two images/well. Data was ana-
lyzed using IncuCyte analysis software to detect and quan-
tify green (apoptotic) cells/image. Each condition was
performed in triplicate. Averages with SEM at each time
point were plotted in Excel (Microsoft, Redmond, WA,
USA). A t-test was performed for the final time point com-
paring the combination of FRAX1036 and docetaxel with
each single agent in Prism (Graphpad, La Jolla, CA, USA).
The apoptotic index was calculated from the apoptosis as-
says by dividing the final apoptotic cell count by the total
cell count. Averages with SEM were plotted in Excel
(Microsoft), and a t-test was performed comparing the
combination of FRAX1036 and docetaxel with each single
agent in Prism (Graphpad).
Live-cell microscopy and image analysis
U2OS cells stably expressing GFP-Histone H2B and RFP-
Tubulin were cultured in Dulbecco’s modified Eagle’s high
glucose medium, 10% fetal bovine serum, NEAA, at 37°C
and 5% CO2. For live imaging experiments, U2OS cells
were plated in a 24-well glass bottom, black-walled plate
(Sensoplate #662892, Greiner Bio-one, Monroe, NC,
USA). On the following day, cells were treated with
DMSO, FRAX1036, and/or docetaxel and imaged every
10 minutes for 72 hours with a 40× ELWD Plan Fluor ob-
jective (NA: 0.6, Nikon, Tokyo, JP) at 37°C and 5% CO2.
Imaging was performed on a Nikon Ti-E perfect focus
inverted microscope equipped with a spinning disk con-
focal CSU-X1 (Andor, Oxford Instruments, Abingdon,
Oxfordshire, UK), motorized X,Y stage (Nikon), environ-
mental chamber (OkoLab, Burlingame, CA, USA) and
iXon3 897 EMCCD camera or Clara interline CCD cam-
era (Andor, Oxford Instruments), all controlled by NIS-
Elements software (Nikon, Tokyo, JP). Time-lapses were
analyzed in NIS-Elements, and supplemental movies were
generated in Quicktime Pro (Apple, Cupertino, CA, USA).
For high-resolution imaging of microtubule organization,
U2OS cells were imaged after 20 hours treatment with a
60× Plan Apo objective (NA: 1.4, Nikon). For immuno-
fluorescence, MDA-MB-175 cells were methanol fixed,
permeabilized in TBS-0.5% TritonX-100 and blocked in 2%
bovine serum albumin, 0.1% Triton X-100. Microtubules
were probed with primary antibody rat-anti tubulin (1:250,
Serotec clone YL1/2), secondary antibody Alexafluor488
anti-rat (1:500, A-11006, Life Technologies, Grand Island,
NY, USA), and mounted with Prolong Gold with DAPI
(Life Technologies, Grand Island, NY, USA).
For the duration of mitosis/mitotic arrest and cell fate
measurements, cells were monitored from the time they
began to round up from the plate to the time when they
were observed to divide, slip out of mitosis with micro-
nuclei, or apoptose. Observations were made using the
phase morphology of the cells as well as chromosomecondensation/decondensation and mitotic spindle morph-
ology in the fluorescent channels. Cells that divided or
slipped were monitored for the remainder of the 72-hour
movie, and subsequent cell events were recorded. Duration
of mitosis/mitotic arrest was graphed in Prism (Graph-
Pad), and significance was determined by one-way analysis
of variance with multiple comparisons to compare each
condition to one another. A t-test was performed on the
two significant but close conditions (docetaxel and
FRAX1036 + docetaxel).
Results
PAK1 amplification and overexpression are associated
with poor outcome in luminal breast cancer
The genomic and transcriptomic architecture of 2,000
breast tumors was recently characterized as part of
METABRIC [15]. Clustering analysis of joint copy number
and gene expression data from the cis-associated genes re-
vealed 10 novel molecular subgroups for breast cancer, in-
cluding an estrogen receptor-positive subgroup composed
of amplification at 11q13/14. This amplified region includes
CCND1 (11q13.3) and PAK1 (11q14.1). Consistent with
previous reports [14], PAK1 mRNA expression was corre-
lated with copy number gain (Figure 1A) and elevated in
luminal breast cancer subtypes (Figure 1B) in METABRIC
samples. To determine the prognostic significance of PAK1
in breast cancer, gene amplification was correlated with
clinical outcome using a Cox proportional hazard model
constructed with METABRIC censored survival data, pa-
tient age, NPI [22], PAM50 breast cancer subtype classifica-
tion, and CCND1/PAK1 amplification status. As expected,
the NPI score, patient age and certain PAM50 subtypes
were associated with worse hazard ratio (Figure 1B). High
level, focal PAK1 amplification was significantly associated
with poor patient outcome (P = 1.29 × 10−4) (Figure 1B;
Additional file 1: Figure S1A), although this was not noted
for either focal gain of CCND1 or broad amplification of
both CCND1 and PAK1. Furthermore, elevated PAK1
mRNA expression was also correlated with poor survival in
the same tissue samples (data not shown).
The association of PAK1 dysregulation with survival of
breast cancer patients was evaluated at the protein level in
an independent sample set of 1,108 estrogen receptor-
positive, early-stage breast tumors. PAK1 immunohisto-
chemistry was validated previously [14] and breast tumor
tissues were analyzed on a standard histology score of 0 to
3. Patients whose tumors had the lowest protein expres-
sion of PAK1 (staining intensity 0 to 1) displayed better
overall survival than patients whose tumors had high
PAK1 expression levels (staining intensity 2 to 3) (Additional
file 1: Figure S1B; two group hazard ratio = 0.80). Taken
together, these results indicate that PAK1 genomic amp-
lification and overexpression are correlated with poor
patient outcome in luminal breast cancer.
Copy number PAM50 classification
A
B P value
Figure 1 p21-Activated kinase (PAK)1 copy number and expression is elevated and associated with poor clinical outcome in breast tumors
analyzed by the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). (A) Illumina mRNA expression of PAK1 is correlated
with copy number alteration and breast cancer subtype in METABRIC tissue samples. “Amplification” is defined as gene amplification greater than
or equal to 5 copies, while “Gain” is defined as >2 and <5 copies. (B) PAK1 focal amplification is associated with poor patient prognosis. Hazard
ratio coefficient (log2 scale) is plotted for clinical and molecular parameters. Hazard ratio is significantly higher for PAK1 focal amplification relative
to CCND1 focal amplification or dual PAK1/CCND1 amplification in luminal breast tumors (n = 980). P values are shown. CCND1, cyclin D1;
Decade, patient age at time of diagnosis; Lum A, luminal A; Lum B, luminal B; NPI, Nottingham prognostic index.
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microtubule regulators and induce apoptotic markers in
luminal breast cancer lines
The small molecule pyridopyrimidinone inhibitor FRAX1036
(Figure 2A) was derived from chemical optimization of aryla-
mino pyridopyrimidinone PAK inhibitors, as representedby FRAX597 [2,23]. FRAX1036 is devoid of the character-
istic arylamino moiety of earlier generation compounds,
resulting in improved kinase selectivity (Additional file 2:
Table S1) and general drug properties. Its biochemical po-
tency (Ki) against PAK1 and PAK2 is 23.3 and 72.4 nM,
respectively, with high selectivity against PAK4 (Ki =
AB
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Figure 2 FRAX1036 inhibition of group I p21-activated kinase (PAK)
isoforms. (A) Chemical structure of the group I PAK inhibitor, FRAX1036.
(B) Concentration-response analysis of FRAX1036 against PAK1, PAK2 or
PAK4. Concentration response curves were generated in duplicate and
represent one of at least three experiments for PAK1 and PAK2 with
similar results. Data shown for PAK4 represent one of two experiments
with similar results. Each curve is normalized to zero and 100% based
on no enzyme or DMSO, respectively. (C) Pharmacodynamic changes
induced by FRAX1036 dose–response. MDA-MB175 cells were treated
with increasing concentrations of FRAX1036 for 24 hours. Cell lysates
were immunoblotted with antibodies against biomarkers involved in
PAK1 effector and survival signaling.
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FRAX1036, breast cancer cell lines with known PAK1
gene amplification status were tested for levels of PAK1
expression and activity (Additional file 3: Figure S2). Po-
tent cellular inhibition of group I PAK substrate phosphor-
ylation (MEK1-S298 and CRAF-S338) was observed at 2.5
to 5 μM concentrations of FRAX1036 in PAK1-amplified
MDA-MB-175 cells (Figure 2C). Consistent with previous
reports evaluating PAK1 function in breast cancer cell
lines via genetic approaches [9], dose-dependent inhibition
of PAK1 effector signaling was correlated with poly(ADP-
ribose) polymerase (PARP) cleavage.
The PAK effector, stathmin, is a microtubule destabiliz-
ing protein and phosphorylation at serine 16 by PAK and
other kinases, and regulates stathmin-tubulin binding
[18,24]. We therefore hypothesized that PAK1 inhibition
in combination with microtubule stabilizing chemothera-
peutic agent taxanes, such as docetaxel (Taxotere, DTX),
could synergistically alter microtubule dynamics in breast
cancer cells leading to greater cell death [25]. FRAX1036
and docetaxel combination treatment of PAK1-amplified
lines, MDA-MB-175 and HCC2911, elevated a major
apoptotic marker (cleaved PARP) and attenuated a cell
cycle regulator (cyclin D1) (Figure 3A). Single-agent doce-
taxel treatment increased stathmin-S16 phosphorylation
indicative of the accumulation of cells in mitosis [26]. To
further validate the observation of a combined effect of
PAK1 inhibition and microtubule perturbation, the com-
bination of docetaxel with PAK1 short interfering RNA
knockdown was also investigated (Figure 3B). PAK1-
dependent phosphorylation of stathmin was observed
in breast cancer cells following selective knockdown
(Figure 3B) or FRAX1036 treatment (Additional file 4:
Figure S2B). Comparable apoptotic signaling changes were
observed for either PAK1 small molecule inhibition or
knockdown in combination with docetaxel. Since com-
bined inhibition altered signaling to caspase substrates
(cleaved PARP), we further examined cell viability by mon-
itoring apoptosis using high content time-lapse imaging.
HCC2911 and MDA-MB-175 breast cancer cells treated
with the combination of FRAX1036 and docetaxel showed
increased kinetics of apoptosis compared with either sin-
gle agent (Figure 3C,E). After 72 hours of treatment, the
apoptotic index (ratio of apoptotic cells/total cells) was an-
alyzed to account for cell proliferation (Figure 3D,F).
FRAX1036 and docetaxel combination treatment resulted
in a significantly greater apoptotic index over FRAX1036
or docetaxel alone in both cell lines. Synergistic modula-
tion of cell viability was also demonstrated via FRAX1036
and docetaxel dose ranging and Bliss independence ana-
lysis (Additional file 4: Figure S3). Taken together, these
data indicate that combinatorial increases in tumor cell
killing are observed with FRAX1036 and docetaxel
treatment.
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Figure 3 FRAX1036 and docetaxel (DTX) combine to alter stathmin phosphorylation, induce the apoptotic marker cleaved PARP and increase
kinetics of apoptosis. (A) MDA-MB-175 and HCC2911 cells were treated with DMSO, 5 μM FRAX1036, 0.2 μM docetaxel and a combination of 5 μM
FRAX1036 and 0.2 μM docetaxel for 24 hours. Cell lysates were immunoblotted with apoptotic and PAK1 downstream markers. (B) MDA-MB-175 cells
were treated with DMSO or 0.2 μM docetaxel for 48 hours after non-targeting control short interfering RNA (siRNA) or PAK1 siRNA transfection for
72 hours. Cell lysates were harvested and subjected to immunoblot analysis for apoptotic markers and microtubule regulators. The molecular weight of
the lower band from the phospho-stathmin immunoblot corresponds to total stathmin. The efficacy of knockdown by PAK1 siRNA was 47% (lane 2)
and 80% (lane 4) as determined by densitometry. (C) Kinetic apoptosis assay. HCC2911 cells were plated in 96-well plates and were untreated (control)
or treated with DMSO, 2.5 μM FRAX1036, 0.2 μM docetaxel, or a combination of 2.5 μM FRAX1036 and 0.2 μM docetaxel. Apoptosis was assayed by
counting the number of green caspase 3/7-positive objects at each time point (Essen Cell player kinetic caspase 3/7 assay). (D) Apoptotic index. The
number of apoptotic cells was normalized to the total number of cells at the final time point in (C) to account for cell proliferation. (E,F) The same as
(C,D) with MDA-MB-175 cells. The average and SEM of three replicates are shown and a t-test performed at the final time point and on the apoptotic
index (*P < 0.03, **P < 0.003, ***P≤ 0.0001).
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organization, duration of mitotic arrest and kinetics
of apoptosis
Both PAK1 signaling and docetaxel were previously re-
ported to affect microtubule dynamics and progression
through mitosis [25,27]. Regulation of microtubule dy-
namics ultimately affects microtubule length and
organization of microtubule arrays. To directly visualize
the effects of FRAX1036 and docetaxel treatments on
microtubules, we utilized a U2OS osteosarcoma cell line
that stably expresses RFP-Tubulin and GFP-Histone
H2B. The flat and spread morphology of U2OS cells was
more amenable to high-resolution microscopy, allowing
us to visualize microtubules in live cells without fixation.
Analysis of pharmacodynamic markers and apoptosis
(Additional file 5: Figure S5A,B) confirmed that U2OS
cells are similarly affected by FRAX1036, docetaxel and
combination treatment as the breast cancer lines exam-
ined in this study. In DMSO-treated cells, microtubule
arrays were organized by the microtubule organizing
center and radiate uniformly to the cell periphery. After
20 hours of treatment with FRAX1036, microtubules
were disorganized and were not evenly distributed
throughout the cytoplasm, between the microtubule or-
ganizing center and the periphery (Figure 4A, arrow). As
expected, docetaxel stabilized microtubules resulting in
elongated bundles of microtubules that curved around
the cytoplasm. Cells treated with both FRAX1036 and
docetaxel had shorter, straight microtubules, suggesting
a change in the regulation of microtubule dynamics
from docetaxel treatment alone. In addition, immuno-
fluorescence of fixed MDA-MB-175 cells treated with
FRAX1036 and docetaxel showed similar effects on
microtubule organization (Additional file 6: Figure S4).
To further probe the relationship between cell cycle pro-
gression and apoptosis we imaged RFP-Tubulin and GFP-
Histone H2B U2OS cells over a 72-hour treatment period
using spinning disk confocal microscopy (Additional file 7:
Movie 1). We tracked individual cells for each of the treat-
ment conditions and visualized mitotic spindle formationto analyze timing and fate (division, slippage or cell death)
after entering mitosis (Figure 4B,C; Additional file 5:
Figure S5C). FRAX1036-treated cells completed normal
mitoses with the majority of apoptosis occurring during
interphase (66.7%). Because the cells are not synchronized
it was not clear from our analysis whether a completed
mitosis was required for apoptosis. Docetaxel-treated cells
arrested in mitosis five-fold longer than control cells
slipped out of mitosis (71.4%) without completing cell
division and formed micronucleated cells that later died
(Figure 4A; Additional file 5: Figure S5C, + symbol). In
contrast, when FRAX1036 was combined with docetaxel,
there was a small decrease in the duration of mitosis and
the majority of these cells died during mitotic arrest
(65.9%), possibly accounting for the increased rate of cell
death. To confirm these results in breast cancer cells, we
imaged MDA-MB-175 cells by phase-contrast microscopy
(Additional file 8: Movie 2). Without clear visible markers
of entry into mitosis, MDA-MB-175 cells were difficult to
track and quantitate due to the densely packed and
rounded morphology. However, the overall trends in cell
fate could be observed: docetaxel treatment resulted in
slipped cells with micronuclei that later died, while dead
cells accumulated more quickly in the FRAX1036 and do-
cetaxel combination. The dependency of FRAX1036 and
docetaxel combination effects on the order of drug treat-
ment was also determined. A pronounced decrease in cell
viability was observed by simultaneous treatment of com-
pounds and when docetaxel was dosed prior (4 hours) to
FRAX1036 (Additional file 9: Figure S6).
Discussion
The advent of high-throughput techniques for genetic and
epigenetic characterization of tumor specimens has led to
an exponential increase in our understanding of molecular
events underlying the process of carcinogenesis. This is es-
pecially true for breast cancer, an indication in which
tumor tissues can be successfully obtained and analyzed
with high frequency. Typically, novel putative driver genes
for breast cancer have been preliminarily evaluated using
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Figure 4 FRAX1036, docetaxel (DTX) and their combination affects microtubule organization, mitosis and cell fate. (A) Spinning-disk confocal
images of live U2OS cells expressing red fluorescent protein (RFP)-Tubulin (red) and green fluorescent protein-Histone H2B (green) bottom panel.
The top panel is RFP-Tubulin channel alone with an individual cell outline by a dotted line for each condition. Arrows highlight changes in
microtubule organization that are characteristic of each treatment. A micronucleated cell is indicated by +. Cells were treated with DMSO, 2.5 μM
FRAX1036, 0.2 μM docetaxel, or a combination of 2.5 μM FRAX1036 and 0.2 μM docetaxel for 20 hours before imaging. Scale bar = 20 μm.
(B) Duration of mitosis/mitotic arrest of cells treated with DMSO, 2.5 μM FRAX1036, 0.2 μM docetaxel, or a combination of 2.5 μM FRAX1036 and
0.2 μM docetaxel. Cells were followed from time of entering mitosis to the time of division, slippage or apoptosis. Each grey symbol represents a
single cell and black bars represent the average. N = 42 mitotic cells imaged from five fields of view. Data is from one of two experiments with similar
results. One-way analysis of variance with multiple comparisons showed that all averages are significantly different except for DMSO:FRAX1036. A t-test
was performed on FRAX1036 + DTX combination vs DTX alone (P = 0.0002). (C) Distribution of major cell fates after entry into mitosis of U2OS cells
treated with FRAX1036, docetaxel and their combination. N = 42 mitotic cells for each treatment condition.
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prehensive and rigorous assessment of intracellular targets
for therapeutic intervention requires selective, potent andcell-active small molecules with good biochemical and cel-
lular properties. FRAX1036 displays selectivity for PAK1-3
relative to group II PAK members as well as other kinases
Ong et al. Breast Cancer Research  (2015) 17:59 Page 10 of 12(Additional file 2: Table S1) and can be used as a tool
compound for in vitro target validation experiments.
Interestingly, PAK1 genomic amplification or protein
overexpression are strongly associated with poor out-
come for luminal (or estrogen receptor-positive) breast
cancer patients (Figure 1; Additional file 1: Figure S1). A
subset of breast carcinomas without genomic amplifica-
tion also display high mRNA and protein expression of
PAK1 (Figure 1A; Additional file 1: Figure S1B). The mo-
lecular mechanisms underpinning dysregulated PAK1 ex-
pression in the absence of genomic amplification are not
well characterized, although regulation by microRNAs
[28] and gene translocation (Peter Haverty, unpublished
data) have both been observed. PAK1 copy number alter-
ations have also been observed in other tumor indications,
such as ovarian cancer and melanoma [16,29] and further
validation efforts are necessary to apply the findings re-
ported here to these other indications.
Hormone receptor-positive breast cancer patients with
localized disease receive front-line treatment with endo-
crine therapies, such as tamoxifen or aromatase inhibi-
tors. There is some evidence that PAK1 may directly
phosphorylate estrogen receptor-α [30] or components
of the estrogen receptor multi-protein complex [31].
However, the potential roles for PAK1 inhibition in com-
bination with later lines of therapy, such as taxanes, have
yet to be explored. Given the evolutionarily conserved
role of PAK1 in regulating cytoskeletal dynamics and the
common use of microtubule inhibitors in later lines of
breast cancer treatment, we evaluated the mechanism
and potential therapeutic benefit of FRAX1036 combin-
ation with docetaxel. We show that signaling changes
elicited by FRAX1036 and docetaxel potentiate apoptosis
of breast cancer cells and that microtubule morphology
is affected by both pathways (Figure 4A). Combination
treatment of FRAX1036 significantly diminished time in
docetaxel-induced mitotic arrest (Figure 4C; Additional
file 5: Figure S5), pushed cell fate from mitotic slippage
to apoptosis (Figure 4B) and accordingly increased the
kinetics of breast tumor cell apoptosis (Figure 3C-F;
Additional file 3: Figure S2). Given that luminal breast
cancer patients generally do not respond durably to
chemotherapy, combination of FRAX1036 with taxanes
may help address unmet needs for patients with ad-
vanced and metastatic disease.
Conclusions
PAKs have been implicated in various aspects of tumori-
genesis. In this study, we demonstrate that PAK1 amplifi-
cation and overexpression are associated with poor
clinical outcome in a large collection of luminal breast
cancers. Treatment of PAK1-amplified breast cancer cells
with a novel small molecule inhibitor of group I PAKs,
FRAX1036, resulted in apoptosis. Efficacy was alsopotentiated in combination with microtubule inhibitors
that are used as standard-of-care chemotherapy in ad-
vanced breast cancer. Taken together, our findings support
the further therapeutic evaluation of PAK inhibitors in
breast cancer.Additional files
Additional file 1: Figure S1. PAK1 dysregulation is associated with
poor patient outcome in breast cancer. (A) Kaplan-Meier curve for PAK1
amplification status in METABRIC breast tumor samples. Amplified is
defined as PAK1 gene amplification >5 copies. Survival differences
between patients was statistically significant (P = 0.0156). (B) Association of
PAK1 protein expression with clinical outcome. PAK1 immunohistochemistry
(IHC) was performed as described previously (Ong and colleagues [29])
using breast cancer tissue microarrays (n = 1,108) provided by the University
of Nottingham. Staining intensity was scored for replicate cores on a
histology score of 0 to 3. Overall survival was plotted for patients with either
low (score 0, 1) or high (score 2, 3) PAK1 tumor expression.
Additional file 2: Table S1. Kinase inhibitory activities for FRAX1036
tested at 1 μM concentration. Biochemical assays were performed to
determine the extent of FRAX1036 inhibition of 247 purified kinases.
Data is shown for <50%, 50 to 75% and >75% inhibition at a compound
concentration of 1 μM.
Additional file 3: Figure S2. PAK1 levels and modulation of stathmin
phosphorylation in breast cancer cells. (A) The protein expression level of
PAK1, PAK2 and phospho-PAK1/2 were detected and compared in 15
breast cells. HCC2911 and MDA-MB-175 cells showed higher PAK1 activity
and expression level. (B) FRAX1036 was administered to SUM52PE and
T47D breast cancer cells at 0, 0.6, 1.2, 2.5, 5 and 10 μM for 24 hours.
DMSO alone was used as a control.
Additional file 4: Figure S3. Combination effects of FRAX1036 and
docetaxel (DTX) on cell viability assay in HCC2911 and MDA-MB175 cells.
(A) HCC2911 and (B) MDA-MB175 cells were treated with FRAX1036,
DTX, or the combination of both drugs and measured in a 4-day Cell
Titer-Glo assay. Percentage of inhibition for cell viability and ΔBliss data
were calculated and plotted as a dose range for both drugs.
Additional file 5: Figure S5 Kinetic apoptosis assay and live-cell
microscopy were used to further determine the extent of apoptosis in
response to FRAX1036, docetaxel (DTX), and a combination. (A) Kinetic
apoptosis assay of U2OS cells treated as in Figure 3 and imaged every
2 hours. Average and SEM of three replicates are shown (*P < 0.01).
(B) U2OS cells were treated with 2 μM FRAX1036 and 0.2 μM DTX as
indicated for 24 hours. Lysates were analyzed for proximal and distal
pharmacodynamics biomarkers. (C) Time lapse images of U2OS cells stably
expressing RFP-Tubulin and GFP-Histone H2B after treatment with DMSO,
2.5 μM FRAX1036, 0.2 μM docetaxel, or combination of 2.5 μM FRAX1036
and 0.2 μM DTX. Images are overlays of phase, RFP and GFP of a single field
of view showing microtubules, nuclei and cell morphology from
time-lapse movies (Additional file 7: Movie 1) at each time point. Symbols
highlight different cell fates quantified in Figure 4C (*Mitotic; +slipped with
micronuclei; ^apoptotic). Scale bar = 20 μm.
Additional file 6: Figure S4. Microtubule organization in MDA-MB-175
cells treated with FRAX1036 and DTX. Spinning-disk confocal immuno-
fluorescence images of fixed MDA-MB-175 cells. Cells were treated
with DMSO, 2.5 μM FRAX1036, 0.2 μM DTX, or a combination of 2.5 μM
FRAX1036 and 0.2 μM DTX for 24 hours before fixation. Scale bar =
20 μm.
Additional file 7: Movie 1. Live-cell microscopy of U2OS cells treated
with FRAX1036, docetaxel (DTX), and a combination over 72 hours.
Spinning disk confocal live-cell imaging of Phase, GFP-Histone H2B and
RFP-Tubulin over 72 hours of treatment. Top-left panel: DMSO; top-right
panel: 2.5 μM FRAX1036; bottom-left panel: 0.2 μM docetaxel; bottom-right
panel: 2.5 μM FRAX1036 and 0.2 μM DTX. Images were acquired every 10 mi-
nutes for 72 hours. The video plays at 15 frames/seconds and is therefore ac-
celerated 9,000 times.
Ong et al. Breast Cancer Research  (2015) 17:59 Page 11 of 12Additional file 8: Movie 2. Live-cell microscopy of MDA-MB-175 cells
treated with FRAX1036, docetaxel (DTX) and a combination over 72 hours.
Phase contrast live-cell imaging of: top-left panel, DMSO; top-right panel,
2.5 μM FRAX1036; bottom-left panel, 0.2 μM DTX; bottom-right panel:
2.5 μM FRAX1036 and 0.2 μM docetaxel. Images were acquired every
10 minutes for 72 hours using a 20× ELWD Plan Fluor objective (NA: 0.45,
Nikon). The video plays at 15 frames/second and is therefore accelerated
9,000 times.
Additional file 9: Figure S6. FRAX1036 and docetaxel order-of-addition
modulates cell viability in vitro. Cell viability was quantified 48 hours
following FRAX1036 and docetaxel (DTX) administered either simultaneously
(bar 4), FRAX1036 preceding DTX by 4 hours (bar 5) or DTX preceding
FRAX1036 by 4 hours (bar 6). The average and SEM of three replicates are
shown. Simultaneous dosing and DTX followed by PAK1 inhibitor treatment
were most efficacious (**P < 0.001).Abbreviations
GFP: green fluorescent protein; MAPK: mitogen-activated protein kinase;
METABRIC: Molecular Taxonomy of Breast Cancer International Consortium;
NEAA: non-essential amino acids; NPI: Nottingham prognostic index;
PAK: p21-activated kinase; PARP: poly(ADP-ribose) polymerase; RFP: red
fluorescent protein.
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